文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Breese G R, Criswell H E, Mueller R A

Brain and Development Research Center, University of North Carolina, School of Medicine, Chapel Hill.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14 Suppl:S65-80. doi: 10.1016/0278-5846(90)90089-y.

Lesch-Nyhan disease has a defined neurological lesion that is accompanied by abnormal motor function, aggression and self-injurious behavior. 2. The dopamine deficiency in Lesch-Nyhan disease has been modelled by destroying dopamine-containing neurons in neonatal rats with 6-hydroxydopamine. 3. Because D1-dopamine antagonists will block self-injurious behavior induced by L-DOPA in neonatal-6-OHDA-lesioned rats, D1-dopamine antagonists are proposed as a potential therapy for aggression and self-injurious behavior in patients with these symptoms. 4. The determination that the drug SCH-12679, which exhibited effectiveness against aggressiveness in mentally retarded patients, is a D1-dopamine antagonist supports the view that new D1-dopamine antagonists being developed will be an effective therapy for some types of aberrant behavior in this population.

莱施-奈恩病有明确的神经病变，伴有异常的运动功能、攻击行为和自我伤害行为。2. 通过用6-羟基多巴胺破坏新生大鼠中含多巴胺的神经元，对莱施-奈恩病中的多巴胺缺乏进行了模拟。3. 由于D1-多巴胺拮抗剂会阻断新生6-OHDA损伤大鼠中左旋多巴诱导的自我伤害行为，因此有人提出D1-多巴胺拮抗剂可作为治疗有这些症状患者的攻击行为和自我伤害行为的潜在疗法。4. 药物SCH-12679对智障患者的攻击性表现出有效性，该药物是一种D1-多巴胺拮抗剂，这支持了以下观点：正在研发的新型D1-多巴胺拮抗剂将成为治疗该人群某些类型异常行为的有效疗法。

Breese G R, Criswell H E, Mueller R A

Brain and Development Research Center, University of North Carolina, School of Medicine, Chapel Hill.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14 Suppl:S65-80. doi: 10.1016/0278-5846(90)90089-y.

Lesch-Nyhan disease has a defined neurological lesion that is accompanied by abnormal motor function, aggression and self-injurious behavior. 2. The dopamine deficiency in Lesch-Nyhan disease has been modelled by destroying dopamine-containing neurons in neonatal rats with 6-hydroxydopamine. 3. Because D1-dopamine antagonists will block self-injurious behavior induced by L-DOPA in neonatal-6-OHDA-lesioned rats, D1-dopamine antagonists are proposed as a potential therapy for aggression and self-injurious behavior in patients with these symptoms. 4. The determination that the drug SCH-12679, which exhibited effectiveness against aggressiveness in mentally retarded patients, is a D1-dopamine antagonist supports the view that new D1-dopamine antagonists being developed will be an effective therapy for some types of aberrant behavior in this population.

莱施-奈恩病有明确的神经病变，伴有异常的运动功能、攻击行为和自我伤害行为。2. 通过用6-羟基多巴胺破坏新生大鼠中含多巴胺的神经元，对莱施-奈恩病中的多巴胺缺乏进行了模拟。3. 由于D1-多巴胺拮抗剂会阻断新生6-OHDA损伤大鼠中左旋多巴诱导的自我伤害行为，因此有人提出D1-多巴胺拮抗剂可作为治疗有这些症状患者的攻击行为和自我伤害行为的潜在疗法。4. 药物SCH-12679对智障患者的攻击性表现出有效性，该药物是一种D1-多巴胺拮抗剂，这支持了以下观点：正在研发的新型D1-多巴胺拮抗剂将成为治疗该人群某些类型异常行为的有效疗法。